Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653936 | 0.92 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL3651954 | 0.90 | POLB (0.41) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL3658937 | 0.89 | SCD (0.39) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL3752357 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL3655707 | 0.88 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL3656071 | 0.87 | NAMPT (0.47) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL17667936 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL3656276 | 0.86 | SCD (0.45) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL3752205 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAGAAHTTNPSR1 | |
| SCHEMBL3653768 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAGAAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | claimed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | claimed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | claimed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | claimed |
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| WO-2009060054-A1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297097-A1 | COMPOUNDS | APP, BACE1, SCD | SMN1; SMN2 3780/4885LMNA 3343/4885GAA 356/4885 |
| US-20120225878-A1 | COMPOUNDS | CYP11B2, CYP11B1, SCD | SMN1; SMN2 1592/4885LMNA 1027/4885GAA 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.